Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of intermediate-grade lymphomas

T P Miller1

  • 1Arizona Cancer Center, University of Arizona, Tucson, USA.

Oncology (Williston Park, N.Y.)
|November 27, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Leukemia & lymphoma·2016
Same author

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Stromal gene signatures in large-B-cell lymphomas.

The New England journal of medicine·2008
Same author

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.

Blood·2001

Intermediate-grade lymphomas, defined by the Working Formulation, exhibit intermediate survival. However, clinicians expect these aggressive lymphomas to be potentially curable with CHOP chemotherapy.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • The Working Formulation defines intermediate-grade lymphomas into four histologic subgroups: follicular large-cell, diffuse small-cleaved-cell, diffuse mixed small- and large-cell, and diffuse large cell.
  • Outcome analysis of 1,153 non-Hodgkin's lymphoma patients indicated these subtypes possess intermediate survival features.

Purpose of the Study:

  • To evaluate the alignment between the Working Formulation's classification of intermediate-grade lymphomas and clinical expectations.
  • To assess if intermediate-grade lymphomas, as defined, meet the clinical criteria of aggressive disease potentially curable with CHOP chemotherapy.

Main Methods:

  • Analysis of outcome data from 1,153 patients with non-Hodgkin's lymphomas.
  • Comparison of Working Formulation definitions with clinical expectations regarding lymphoma behavior and treatment response.

Related Experiment Videos

Main Results:

  • The Working Formulation's histologic subtypes (Groups D, E, F, G) were associated with intermediate median and overall survival.
  • Clinical expectations for intermediate-grade lymphomas include aggressive growth, high early fatality risk, and curability with CHOP chemotherapy.

Conclusions:

  • The Working Formulation's classification of intermediate-grade lymphomas is partly successful in reflecting clinical expectations but not by design.
  • There is a discrepancy between the statistical 'intermediate' survival and the clinical expectation of aggressive, potentially curable disease.